Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial
试验速览
- 阶段
- 1 期
- 入组人数
- 81
- 试验地点
- 1
- 主要终点
- Cough suppression
研究概览
简要总结
The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Covid-19 positive
- •Moderate to severe ARDS
排除标准
- •patients with COPD or taking bronchodilators and steroids for chronic respiratory illnesses
研究组 & 干预措施
Lidocaine group
干预措施: Lidocaine (Drug)
Salbutamol group
干预措施: Lidocaine (Drug)
Beclomethasone plus salbutamol
干预措施: Lidocaine (Drug)
结局指标
主要结局
Cough suppression
时间窗: within five minutes of initiation of treatment it will be assessed
it will be assessed by using cough severity score
次要结局
- correction of hypoxia(immediately before and after intervention)
研究者
Sairah Sadaf
Associate Professor
Sheikh Zayed Medical College